Labcorp Holdings Inc.
Statements
Segments
US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Labcorp Holdings Inc. (LH). It shows which part of the business is growing — and which one is holding it back.
Revenue by business segment
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| LabCorp Diagnostics [Member] | $9.25B 65.5% | $10.36B 78.4% · +12.0% | $9.20B 77.3% · -11.2% | $9.42B 77.2% · +2.3% | $10.14B 77.6% · +7.7% | $10.88B 77.8% · +7.2% |
| Biopharma Laboratory Services | – | – | $2.70B 22.7% | $2.77B 22.8% · +2.9% | $2.92B 22.4% · +5.3% | $3.10B 22.2% · +6.0% |
| Covance Drug Development [Member] | $4.88B 34.5% | $2.86B 21.6% · -41.4% | – | – | – | – |
| Corporate Segment [Member] | – | – | – | – | – | – |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| LabCorp Diagnostics [Member] | $2.80B 30.3% | $3.21B 30.9% | $2.03B 22.0% | $1.59B 16.9% | $1.61B 15.8% | $1.78B 16.4% |
| Biopharma Laboratory Services | – | – | $389.1M 14.4% | $396.3M 14.3% | $458.9M 15.7% | $498.5M 16.1% |
| Covance Drug Development [Member] | $721.6M 14.8% | $501.0M 17.5% | – | – | – | – |
| Corporate Segment [Member] | -$299.4M | -$404.5M | -$468.8M | -$644.1M | -$670.8M | -$482.2M |
Large figure: segment operating income. Below it the margin, that is operating income measured against the revenue of the same segment.
Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.
Data as of: August 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.